These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 14687233)

  • 1. Preventing osteoporotic fractures with antiresorptive therapy: implications of microarchitectural changes.
    Boonen S; Haentjens P; Vandenput L; Vanderschueren D
    J Intern Med; 2004 Jan; 255(1):1-12. PubMed ID: 14687233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
    Ettinger MP
    Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
    Seibel MJ; Naganathan V; Barton I; Grauer A
    J Bone Miner Res; 2004 Feb; 19(2):323-9. PubMed ID: 14969403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Osteoporosis in the aged male].
    Szulc P; Delmas PD
    Presse Med; 2002 Nov; 31(37 Pt 1):1760-9. PubMed ID: 12489321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Measurement of bone mineral density is necessary for monitoring of bisphosphonate treatment].
    Soen S
    Clin Calcium; 2011 Jan; 21(1):116-9. PubMed ID: 21187604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone mineral density in lung-transplant recipients before and after graft: prevention of lumbar spine post-transplantation-accelerated bone loss by pamidronate.
    Trombetti A; Gerbase MW; Spiliopoulos A; Slosman DO; Nicod LP; Rizzoli R
    J Heart Lung Transplant; 2000 Aug; 19(8):736-43. PubMed ID: 10967266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint.
    Marcus R; Wong M; Heath H; Stock JL
    Endocr Rev; 2002 Feb; 23(1):16-37. PubMed ID: 11844743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiresorption therapy and reduction in fracture susceptibility in the osteoporotic elderly patient: open study.
    Muscoso E; Puglisi N; Mamazza C; Lo Giudice F; Testai M; Abbate S; Santangelo A; Panebianco P; Maugeri D
    Eur Rev Med Pharmacol Sci; 2004; 8(2):97-102. PubMed ID: 15267123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents.
    Hochberg MC; Greenspan S; Wasnich RD; Miller P; Thompson DE; Ross PD
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1586-92. PubMed ID: 11932287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Guidelines for drug therapy of postmenopausal osteoporosis].
    Dimai HP; Pietschmann P; Resch H; Leb G; Klaushofer K
    Wien Med Wochenschr; 2002; 152(23-24):596-612. PubMed ID: 12530170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Bisphosphonates in the prevention of vertebral and non-vertebral fractures in postmenopausal women with osteoporosis].
    Curković B
    Reumatizam; 2003; 50(2):49-50. PubMed ID: 15098377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of postmenopausal osteoporosis and the prevention of fractures.
    Gambacciani M; Levancini M
    Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation.
    Delmas PD; Eastell R; Garnero P; Seibel MJ; Stepan J;
    Osteoporos Int; 2000; 11 Suppl 6():S2-17. PubMed ID: 11193237
    [No Abstract]   [Full Text] [Related]  

  • 14. The treatment of osteoporosis. Antiresorptive therapy.
    Miller PD
    Clin Lab Med; 2000 Sep; 20(3):603-22, viii. PubMed ID: 10986624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced Bone Modeling and Unbalanced Bone Remodeling: Targets for Antiresorptive and Anabolic Therapy.
    Ramchand SK; Seeman E
    Handb Exp Pharmacol; 2020; 262():423-450. PubMed ID: 32232792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addressing the musculoskeletal components of fracture risk with calcium and vitamin D: a review of the evidence.
    Boonen S; Bischoff-Ferrari HA; Cooper C; Lips P; Ljunggren O; Meunier PJ; Reginster JY
    Calcif Tissue Int; 2006 May; 78(5):257-70. PubMed ID: 16622587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteoporosis in Premenopausal Women: A Clinical Narrative Review by the ECTS and the IOF.
    Pepe J; Body JJ; Hadji P; McCloskey E; Meier C; Obermayer-Pietsch B; Palermo A; Tsourdi E; Zillikens MC; Langdahl B; Ferrari S
    J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32453819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs.
    Cummings SR; Karpf DB; Harris F; Genant HK; Ensrud K; LaCroix AZ; Black DM
    Am J Med; 2002 Mar; 112(4):281-9. PubMed ID: 11893367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New therapeutic targets for osteoporosis.
    Anagnostis P; Gkekas NK; Potoupnis M; Kenanidis E; Tsiridis E; Goulis DG
    Maturitas; 2019 Feb; 120():1-6. PubMed ID: 30583758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses.
    Delmas PD; Li Z; Cooper C
    J Bone Miner Res; 2004 Feb; 19(2):330-7. PubMed ID: 14969404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.